We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+11.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$826M
AUM Growth
-$75.1M
Cap. Flow
-$116M
Cap. Flow %
-14%
Top 10 Hldgs %
53.79%
Holding
72
New
9
Increased
9
Reduced
17
Closed
17

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$14.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.93M
3
ENDP
Endo International plc
ENDP
+$4.02M
4
DXCM icon
DexCom
DXCM
+$3.85M
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$3.77M

Top Sells

Rank Stock Value
1
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$69.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$18.6M
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$15.2M
5
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 77.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.9M 1.32%
2,090,801
+1,264,800
+153% +$6.93M
MDCO
27
DELISTED
Medicines Co
MDCO
$10.5M 1.27%
215,077
-221,323
-51% -$10.1M
BDSI
28
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$10.3M 1.24%
5,398,794
– –
ACGN
29
DELISTED
Aceragen Inc
ACGN
$9.52M 1.15%
28,359
-4,231
-13% -$1.02M
AMRN
30
Amarin Corp
AMRN
$285M
$9.07M 1.1%
141,682
– –
DRRX
31
DELISTED
DURECT Corp
DRRX
$8.93M 1.08%
850,623
– –
SPNE
32
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$8.63M 1.05%
1,099,807
-200
-0% -$1.45K
BCR
33
DELISTED
CR Bard Inc.
BCR
$6.79M 0.82%
27,300
-12,900
-32% -$3.11M
ADMA icon
34
ADMA Biologics
ADMA
$1.91B
$5.02M 0.61%
1,028,672
-84,621
-8% -$417K
CDTX
35
DELISTED
Cidara Therapeutics
CDTX
$4.39M 0.53%
28,144
– –
NVET
36
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$4.38M 0.53%
1,127,200
– –
PRTK
37
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.31M 0.52%
223,862
-562,272
-72% -$8.86M
MDWD icon
38
MediWound
MDWD
$181M
$4.18M 0.51%
90,443
– –
DXCM icon
39
DexCom
DXCM
$27.7B
$4.18M 0.51%
+197,200
New +$3.85M
SCYX icon
40
SCYNEXIS
SCYX
$37.6M
$4.08M 0.49%
18,466
– –
JUNO
41
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.9M 0.47%
+175,700
New +$3.77M
OMED
42
CALL
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$2.76M 0.33%
+300,000
New +$2.63M
CFRX
43
DELISTED
ContraFect Corporation
CFRX
$2.57M 0.31%
1,786
– –
PGNX
44
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.36M 0.29%
+250,000
New +$2.5M
VXRT
45
DELISTED
Vaxart
VXRT
$2.07M 0.25%
289,021
-27,953
-9% -$286K
ARCT icon
46
Arcturus Therapeutics
ARCT
$158M
$1.39M 0.17%
173,806
-120,066
-41% -$1.11M
CGNT
47
DELISTED
Cogentix Medical, Inc.
CGNT
$1.36M 0.16%
753,773
– –
AVGR
48
DELISTED
Avinger, Inc. Common Stock
AVGR
$950K 0.12%
+4
New +$1.18M
GNMX
49
CALL
DELISTED
Aevi Genomic Medicine Inc
GNMX
$930K 0.11%
+500,000
New +$2.26M
WINT
50
DELISTED
Windtree Therapeutics Inc
WINT
$887K 0.11%
777,797
– –
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Broadfin Capital held 72 positions worth $826M, down 8.3% from $901M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital withdrew a net $116M in Q1 2017, closing 17 positions and reducing 17 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 89% a quarter earlier, followed by Financials.

Against the trend, Broadfin Capital opened a new position in DexCom worth $4.18M.

  • Broadfin Capital's largest Q1 2017 buy was DexCom: 197,200 shares worth $4.18M.
  • Broadfin Capital added most to Heron Therapeutics in Q1 2017, an estimated $14.5M increase.
  • Broadfin Capital's biggest Q1 2017 reduction was Progenics Pharmaceuticals Inc, cutting an estimated $69.4M.
  • Broadfin Capital fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $23.5M.
  • Broadfin Capital's ten largest holdings make up 54% of its $826M portfolio in Q1 2017.
  • Broadfin Capital opened 9 new positions and closed 17 in Q1 2017.
  • Broadfin Capital's portfolio value fell 8.3% quarter-over-quarter to $826M.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.